{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Columbus&page=52&state=Ohio", "query": { "state": "Ohio", "city": "Columbus", "page": 52 }, "page_size": 10 }, "pagination": { "page": 52, "page_size": 10, "total_count": 10856, "total_pages": 1086, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Columbus&page=53&state=Ohio&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Columbus&page=51&state=Ohio&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-09T23:25:07.561Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02830542", "title": "SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clostridium Difficile Infection" ], "interventions": [ { "name": "SER-262", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seres Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 96, "start_date": "2016-08", "completion_date": "2018-08", "has_results": false, "last_update_posted_date": "2023-02-06", "last_synced_at": "2026-11-09T23:25:07.561Z", "location_count": 22, "location_summary": "Athens, Alabama • Fountain Valley, California • La Mesa, California + 19 more", "locations": [ { "city": "Athens", "state": "Alabama" }, { "city": "Fountain Valley", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02830542" }, { "nct_id": "NCT01211873", "title": "Safety and Efficacy Evaluation of DOTAREM® in MRI of Central Nervous System (CNS) Lesions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diagnostic Self Evaluation", "Central Nervous System Diseases" ], "interventions": [ { "name": "Dotarem (gadoterate meglumine)", "type": "DRUG" }, { "name": "Magnevist (gadopentetate dimeglumine)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Guerbet", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 416, "start_date": "2010-09", "completion_date": "2011-11", "has_results": true, "last_update_posted_date": "2019-04-18", "last_synced_at": "2026-11-09T23:25:07.561Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Indian Wells, California + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Indian Wells", "state": "California" }, { "city": "Hollywood", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01211873" }, { "nct_id": "NCT04206605", "title": "A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Angioedema" ], "interventions": [ { "name": "Placebo", "type": "OTHER" }, { "name": "Lanadelumab", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 77, "start_date": "2020-05-04", "completion_date": "2022-10-20", "has_results": true, "last_update_posted_date": "2023-12-27", "last_synced_at": "2026-11-09T23:25:07.561Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Walnut Creek", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04206605" }, { "nct_id": "NCT04689828", "title": "177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "177Lu-PSMA-617", "type": "DRUG" }, { "name": "68Ga-PSMA-11", "type": "DRUG" }, { "name": "ARDT", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "MALE", "summary": "18 Years to 100 Years · Male only" }, "enrollment_count": 469, "start_date": "2021-06-15", "completion_date": "2026-09-09", "has_results": true, "last_update_posted_date": "2026-11-04", "last_synced_at": "2026-11-09T23:25:07.561Z", "location_count": 20, "location_summary": "Denver, Colorado • Gainesville, Florida • New Orleans, Louisiana + 13 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04689828" }, { "nct_id": "NCT00386100", "title": "A Type 2 Diabetes Study of the Longer-Term Glycemic Effect of AVANDAMET vs. Metformin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Avandamet 6 mg/1500 mg (ttd)", "type": "DRUG" }, { "name": "Avandamet 4 mg/1000 mg (ttd)", "type": "DRUG" }, { "name": "Avandamet 2 mg/500 mg (ttd)", "type": "DRUG" }, { "name": "Avandamet 8 mg/ 2000 mg (ttd)", "type": "DRUG" }, { "name": "Metformin 500 mg (ttd)", "type": "DRUG" }, { "name": "Metformin 1000 mg (ttd)", "type": "DRUG" }, { "name": "Metformin 1500 mg (ttd)", "type": "DRUG" }, { "name": "Metformin 2000 mg (ttd)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 688, "start_date": "2006-10", "completion_date": "2009-09", "has_results": true, "last_update_posted_date": "2016-11-23", "last_synced_at": "2026-11-09T23:25:07.561Z", "location_count": 71, "location_summary": "Tuscaloosa, Alabama • Gilbert, Arizona • Glendale, Arizona + 65 more", "locations": [ { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00386100" }, { "nct_id": "NCT04028492", "title": "Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Idiopathic Gastroparesis", "Diabetic Gastroparesis", "Gastroparesis" ], "interventions": [ { "name": "Tradipitant", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Open Label Tradipitant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanda Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 979, "start_date": "2019-08-20", "completion_date": "2025-02-21", "has_results": true, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-11-09T23:25:07.561Z", "location_count": 36, "location_summary": "Birmingham, Alabama • Peoria, Arizona • Little Rock, Arkansas + 30 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Chula Vista", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04028492" }, { "nct_id": "NCT06767514", "title": "Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Ivonescimab Injection", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab Injection", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Summit Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 780, "start_date": "2025-02-27", "completion_date": "2029-06", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-11-09T23:25:07.561Z", "location_count": 97, "location_summary": "Chandler, Arizona • Phoenix, Arizona • Hot Springs, Arkansas + 86 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Alameda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06767514" }, { "nct_id": "NCT01824316", "title": "A Comparison of Management Strategies of Asthma in Pregnancy", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Asthma", "Pregnancy" ], "interventions": [], "intervention_types": [], "sponsor": "Jennifer McCallister MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "88 Years", "sex": "ALL", "summary": "18 Years to 88 Years" }, "enrollment_count": 108, "start_date": "2013-01", "completion_date": "2013-03", "has_results": false, "last_update_posted_date": "2013-04-04", "last_synced_at": "2026-11-09T23:25:07.561Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01824316" }, { "nct_id": "NCT01668784", "title": "Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Everolimus", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 821, "start_date": "2012-10-09", "completion_date": "2021-07-19", "has_results": true, "last_update_posted_date": "2022-08-09", "last_synced_at": "2026-11-09T23:25:07.561Z", "location_count": 39, "location_summary": "Fayetteville, Arkansas • La Jolla, California • Los Angeles, California + 29 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01668784" }, { "nct_id": "NCT01369433", "title": "A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "Tivozanib + paclitaxel", "type": "DRUG" }, { "name": "Tivozanib + temsirolimus", "type": "DRUG" }, { "name": "Tivozanib", "type": "DRUG" }, { "name": "Tivozanib (AV-951)", "type": "DRUG" }, { "name": "Tivozanib + capecitabine", "type": "DRUG" }, { "name": "Tivo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AVEO Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 225, "start_date": "2010-06", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2020-09-01", "last_synced_at": "2026-11-09T23:25:07.561Z", "location_count": 27, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Stanford, California + 24 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01369433" } ] }